在三阴性乳腺癌中开发生物制剂联合疗法
Developing combination therapies with biologics in triple-negative breast cancer
DOI 原文链接
用sci-hub下载
如无法下载，请从 Sci-Hub 选择可用站点尝试。
影响因子:4
分区:医学3区 / 生物工程与应用微生物3区 医学：研究与实验4区
发表日期:2024 Oct
作者:
Gilda Gaudio, Enzo Martino, Gloria Pellizzari, Matteo Cavallone, Grazia Castellano, Abeid Omar, Lika Katselashvili, Dario Trapani, Giuseppe Curigliano
DOI:
10.1080/14712598.2024.2408756
摘要
新型药物已进入三阴性乳腺癌（TNBC）的治疗方案，包括免疫检查点抑制剂（ICIs）、PARP抑制剂和抗体药物偶联物（ADCs）。通过联合治疗和引入新型药物，可以优化疗效。本文综述了开发中的TNBC联合治疗策略。近年来新药的研发推动了针对TNBC异质性的联合疗法研究，旨在改善预后。免疫检查点抑制剂、ADC、酪氨酸激酶抑制剂（TKIs）和PARP抑制剂成为新兴的主要药物，而新型细胞内信号通路抑制剂或癌症疫苗等也逐渐受到关注。未来的TNBC治疗将以联合策略为主，基于新靶点，包括多种无化疗的治疗方案。许多TNBC治疗在临床上效果不佳或安全性尚不可接受，但也有一些显示出良好前景的药物已进入晚期临床试验，少数已改变临床实践。随着更多选择性更强的新药问世，未来的联合策略强调协同作用的概念是非常必要的。
Abstract
Novel compounds have entered the triple-negative breast cancer (TNBC) treatment algorithm, namely immune checkpoints inhibitors (ICIs), PARP inhibitors and antibody-drug conjugates (ADCs). The optimization of treatment efficacy can be enhanced with the use of combination treatments, and the incorporation of novel compounds. In this review, we discuss the combination treatments under development for the treatment of TNBC.The development of new drugs occurring in recent years has boosted the research for novel combinations to target TNBC heterogeneity and improve outcomes. ICIs, ADCs, tyrosine kinase inhibitors (TKIs), and PARP inhibitors have emerged as leading players in this new landscape, while other compounds like novel intracellular pathways inhibitors or cancer vaccines are drawing more and more interest. The future of TNBC is outlined in combination approaches, and based on new cancer targets, including many chemotherapy-free treatments.A large number of TNBC therapies have either proved clinically ineffective or weighted by unacceptable safety profiles. Others, however, have provided promising results and are currently in late-stage clinical trials, while a few have actually changed clinical practice in recent years. As novel, more and more selective drugs come up, combination strategies focusing the concept of synergy are fully warranted for the future.